Treats hypertension. ANDA 76204, held by Teva. Moexipril Hydrochloride.
As of Nov 16, 2026, ANDA 76204 (Moexipril Hydrochloride), held by Teva, was first approved by FDA on May 8, 2003, with 4 approved supplements and 0 published complete response letters.
INDICATIONS AND USAGE Moexipril hydrochloride tablets USP are indicated for treatment of patients with hypertension. It may be used alone or in combination with thiazide diuretics. In using moexipril hydrochloride tablets USP, consideration should be given to the fact that another ACE inhibitor, captopril, has caused agranulocytosis, particularly in patients with renal impairment or collagen-vascular disease. Available data are insufficient to show that moexipril hydrochloride tablets USP do not have a similar risk (see WARNINGS ).
| Date | Submission | Status | Documents |
|---|---|---|---|
| May 8, 2003 | Original application | Approved |
| Moexipril Hydrochloride7.5MG · tablet;oral | Moexipril Hydrochloride | Rx |
| Moexipril Hydrochloride15MG · tablet;oral | Moexipril Hydrochloride | Rx |
| Apr 2, 2015 | Supplement 12Labeling | Approved | None posted |
| Apr 2, 2015 | Supplement 13Labeling · Standard review | Approved | None posted |
| Nov 15, 2011 | Supplement 11Labeling | Approved | None posted |
| Aug 31, 2010 | Supplement 9Labeling | Approved | None posted |
| May 8, 2003 | Original application | Approved |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters